Fulcrum Therapeutics, Inc.
FULC
$6.67
$0.152.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 80.00M | 80.00M | 80.87M | 81.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 80.00M | 80.00M | 80.87M | 81.63M |
| Cost of Revenue | 52.74M | 57.02M | 63.39M | 70.67M | 74.27M |
| Gross Profit | -52.74M | 22.98M | 16.61M | 10.20M | 7.36M |
| SG&A Expenses | 29.97M | 33.39M | 36.45M | 38.60M | 40.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.71M | 90.40M | 99.83M | 109.27M | 114.40M |
| Operating Income | -82.71M | -10.40M | -19.83M | -28.40M | -32.77M |
| Income Before Tax | -73.22M | -510.00K | -9.73M | -17.91M | -20.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -73.22 | -0.51 | -9.73 | -17.91 | -20.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.22M | -510.00K | -9.73M | -17.91M | -20.23M |
| EBIT | -82.71M | -10.40M | -19.83M | -28.40M | -32.77M |
| EBITDA | -81.28M | -8.94M | -18.24M | -26.67M | -30.88M |
| EPS Basic | -1.21 | -0.05 | -0.20 | -0.29 | -0.33 |
| Normalized Basic EPS | -0.74 | -0.01 | -0.10 | -0.16 | -0.21 |
| EPS Diluted | -1.22 | -0.07 | -0.22 | -0.31 | -0.35 |
| Normalized Diluted EPS | -0.74 | -0.02 | -0.11 | -0.17 | -0.22 |
| Average Basic Shares Outstanding | 241.39M | 241.05M | 240.55M | 248.47M | 247.88M |
| Average Diluted Shares Outstanding | 241.39M | 242.43M | 241.93M | 249.85M | 249.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |